Nektar Therapeutics says it has started a quiet period for its clinical study on rezpegaldesleukin.

Sep 8, 2026, 4:16 PM ETMarketRead the original at sec.gov

Neutral

Nektar announced a quiet period before reporting 24-week off-treatment follow-up data from its Phase 2b REZOLVE-AA trial. The filing provides no trial results or financial figures and does not change the company's outlook.

NKTR · Nektar Therapeutics

AI read · Neutral

The AI's read

Nektar Therapeutics filed an 8-K saying it will enter a quiet period from Sept 8, 2026 until public release of its Phase 2b REZOLVE-AA 24-week off-treatment follow-up data. The filing supplies no trial results or financial figures, so the disclosure itself does not change how we read Nektar today.

Get alerts for NKTR

Follow Nektar Therapeutics (NKTR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NKTR

Free on the App Store and Google Play, or on the web.